PPC
XENE icon

Park Place Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Park Place Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$930 Hold
16
– – ﹤0.01% 806
2025
Q4 		$717 Hold
16
– – ﹤0.01% 775
2025
Q3 		$642 Hold
16
– – ﹤0.01% 772
2025
Q2 		$513 Hold
16
– – ﹤0.01% 794
2025
Q1 		$537 Buy
+16
New +$608 ﹤0.01% 810
2024
Q4 		– Sell
-18
Closed -$709 – 883
2024
Q3 		$709 Hold
18
– – ﹤0.01% 840
2024
Q2 		$702 Hold
18
– – ﹤0.01% 845
2024
Q1 		$775 Buy
+18
New +$828 ﹤0.01% 888
2023
Q4 		– Sell
-22
Closed -$752 – 1041
2023
Q3 		$752 Hold
22
– – ﹤0.01% 993
2023
Q2 		$847 Buy
+22
New +$875 ﹤0.01% 990

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Park Place Capital's XENE Position: Q1 2026 in Review

Park Place Capital held its Xenon Pharmaceuticals (XENE) position steady in Q1 2026 at 16 shares worth $930. The position accounts for ﹤0.01% of the portfolio, ranked #806.

Park Place Capital first reported a position in XENE in Q2 2023 and has held it in 10 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Park Place Capital held 16 shares of Xenon Pharmaceuticals worth $930 as of Q1 2026.
  • Park Place Capital left its Xenon Pharmaceuticals share count unchanged in Q1 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of Park Place Capital's portfolio in Q1 2026, its #806 holding.
  • Park Place Capital first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 10 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Park Place Capital's 13F filing for Q1 2026, filed 9 Apr 2026.